Across TCGA pan-cancer cohorts, FAM124A Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated FAM124A data layer compared with 23 for mass-spec protein and 1 for mass-spec protein.
The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher FAM124A Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated FAM124A expression acts as an unfavorable survival marker.
UCEC, GBM, and COAD are the cancer types where FAM124A Mutation most reproducibly stratifies survival.